According to a study, a drug mix is effective against Covid-19. Hospital stays and deaths have been reduced by 70 percent.
In August last year, the Swiss pharmaceutical company Roche and the biotechnology company Regeneron teamed up to develop a novel antibody combination of casirivimab and imdevimab. The efforts have already borne fruit: in the USA, the FDA granted the drug * emergency approval last year. According to a release from Roche, the rolling evaluation of clinical data for the antibody combination by the Standing Committee on Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) began in February 2021.
Fight against corona: drug cocktail made from antibodies shows promising results
Several Swiss media are now reporting that the phase III study (REGN-COV 2067) – the efficacy and safety of a drug is being checked – attested good results for the drug mix. Through the Antibody cocktail made from casirivimab and imdevimab could therefore Reduced the risk of hospitalization or death from coronavirus infection by 70 percent become. In addition, the therapy developed by Regeneron reduced the duration of symptoms by four days. The new drug also achieved all secondary goals for infected but not hospitalized patients, including, for example, the ability to shorten the duration of symptoms from 14 to ten days. Means: Treatment with the antibodies can prevent severe courses in patients with mild or moderate Covid 19 disease.
As reported by the Pharmazeutische Zeitung, the EMA has already recommended the use of casirivimab and imdevimab, even if official approval is pending. This applies to patients aged twelve and over who suffer from mild or moderate Covid-19 and are not dependent on an oxygen supply, but there is a risk of a severe course.
In an accompanying phase II study, the antibody cocktail at certain doses even significantly reduced the viral load in symptomatic or asymptomatic, non-hospitalized, low-risk patients.
Interesting too: British corona mutation B.1.1.7: New study shows clear differences in Covid symptoms.
Further studies of the drug mix regarding Covid-19
In addition to the studies on non-hospitalized patients, a phase II / III clinical study for the treatment of Covid-19 in hospitalized patients and a phase III study for the prevention of Covid-19 in contact with infected people in the household are also ongoing. (fk) * Merkur.de is an offer from IPPEN.MEDIA.
Read here: Corona vaccination: This is how long you should avoid alcohol before and afterwards.